Skip to main content
. 2021 Jun 16;13(6):893. doi: 10.3390/pharmaceutics13060893

Figure 5.

Figure 5

IOP changes over 2 months following microbead injection. (A). IOP was measured at the days given on the X-axis and averaged across all mice in each group. (B). Area Under the Curve (AUC) of IOP change was quantified by pixel counting using imageJ. This is an example of IOP AUC assessment on an individual eye from Naïve mouse. (C). Mean AUC of IOP change for each treatment group. The mice in the “Naïve” group (N = 10) did not receive microbead injection or any treatment; the mice in the “Buffer” group (N = 10) received buffer (HBSS) injection without any treatment; the mice in the “PBS+Microbeads” group (N = 19) received microbead injection and PBS i.p. injection; the mice in the “NR+Microbeads” group (N = 18) received microbead injection and NR treatment; the mice in the “NR only” group (N = 10) received NR treatment without anterior chamber injection. Microbead injection caused significant IOP AUC increases (compare red and green bars to black and gray bars). NR treatment in microbead-injected eyes (green bar) increased AUC IOP compared to PBS treatment (red bar). ** p < 0.01, *** p < 0.001, **** p < 0.0001 by one-way ANOVA with Newman-Keuls post-hoc test. Error bars represent SEM.